CBPartners is a leading global healthcare strategy consulting firm

Thought Leadership

Misconceptions of the 340B Drug Discount Program

Since its inception over 30 years ago, the 340B drug pricing program policy has evolved allowing for unprecedented expansion and influence. With this it has also become highly contested, especially in recent years as more legislation has been put forward to close 340B loopholes.

Access and Reimbursement: Access to Digital Therapeutics in a Post-COVID-19 World

CBPartners’ in collaboration with Eric Bernath, explores the current USA access landscape, processes and pitfalls for companion digital therapeutics (DTx), as well as how the space is likely to evolve in the future, and lays out some best practices as suggested by USA payers to maximize chances of reimbursement.

What’s Next for Alzheimer’s Disease?

Basic science has been redeployed to establish a new understanding of Alzheimer’s Disease, focusing on novel biomarkers and cutting-edge therapeutic approaches to slow or reverse disease progression, where the amyloid beta theory has otherwise failed

2019 NRDL: Insights for Future Pricing Negotiations in China

The 2019 NRDL update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas. CBPartners’ blog post examines how these learnings can help shape future NRDL negotiations.

Clinical Trial Disruptions: Can Small-Cap Biopharma Companies Weather the Impact of COVID-19?

Cumulative costs from patient enrollment scenarios due to COVID-19 will likely generate a significant financial drain on biopharma R&D expenditures. CBPartners’ blog post investigates this impact and explores mitigation strategies.

Latest career opportunities

New York City, San Francisco
Manager, Commercial Planning, USA
Apply
London
Analyst
Apply
San Francisco
Analyst
Apply